Peptides DB
Research-centric peptide and protocol reference hub

Cagrilintide (AM833) record · updated 7h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 6 studiesJump to the evidenceCompare
What is Cagrilintide (AM833) used for?

Cagrilintide (AM833) is a long-acting amylin analog investigated for once-weekly subcutaneous use in obesity and type 2 diabetes, most notably combined with semaglutide as CagriSema.

How it works: Long-acting amylin analog

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Cagrilintide (AM833) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 5 registered trials. It describes the research record, not a recommendation.

Identity
NameCagrilintide (AM833)
Full name—
Sequence—
ClassWeight Loss
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
MechanismLong-acting amylin analog
RouteSubcutaneous injection
Half-life~7–8 days
Time to peak—
DurationWeekly dosing (investigational)
Extraction confidence0.70
Effect profile · 0–5
Metabolic & appetite: Healing 1.0, Muscle 0.0, Metabolic 4.0, Neuro 1.0, Sleep 0.0, Immune 2.0, Skin 3.0Healing & recovery — 1.0 / 5Metabolic & appetite — 4.0 / 5Neuro & mood — 1.0 / 5Inflammation & immune — 2.0 / 5Skin & aesthetics — 3.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin1.00.04.01.00.02.03.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies6
Human / animal / cellular3 / 0 / 0
Highest trial phasePhase 3
Years covered2021–2026
Latest study14d ago
Publication history
20212026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

6 rowsOpen in the library →
StudyTypeYearSummary depth
Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
Finding–14.9% weight loss vs placebo at 68 wk, n=1961, p<0.001
—2022Title only0.20
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
FindingMD -9.07% weight loss at 20-32 weeks with Cagrisema vs semaglutide, 95%CI: -11.91, -6.23; p < 0.00001; I2 = 96%
Human2024Full text read0.80
Clinical studies on anti-obesity medications in Arab countries.
Finding32.2% of patients reported gastrointestinal side effects.
Human2025Full text read0.80
Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.
FindingNot reported in abstract.
review2025Full text read0.70
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Finding-17.18% body weight change with high dose CagriSema vs placebo
Human2026Full text read0.80
AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.
FindingCagrilintide (AM833) had an EC50 value of 0.5 nM for receptor activation.
—2021Title only0.20

Articles mentioning Cagrilintide (AM833)